TGF-β在癌症标志物中的作用和新出现的肿瘤联合治疗设计。

IF 4.5 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Expert Reviews in Molecular Medicine Pub Date : 2022-11-08 DOI:10.1017/erm.2022.37
Xiaofeng Dai, Dong Hua, Xiaoxia Lu
{"title":"TGF-β在癌症标志物中的作用和新出现的肿瘤联合治疗设计。","authors":"Xiaofeng Dai,&nbsp;Dong Hua,&nbsp;Xiaoxia Lu","doi":"10.1017/erm.2022.37","DOIUrl":null,"url":null,"abstract":"<p><p>Transforming growth factor-beta (TGF-<i>β</i>) is a double-edged sword in cancer treatment because of its pivotal yet complex and roles played during cancer initiation/development. Current anti-cancer strategies involving TGF-<i>β</i> largely view TGF-<i>β</i> as an onco-therapeutic target that not only substantially hinders its full utilisation for cancer control, but also considerably restricts innovations in this field. Thereby, how to take advantages of therapeutically favourable properties of TGF-<i>β</i> for cancer management represents an interesting and less investigated problem. Here, by categorising cancer hallmarks into four critical transition events and one enabling characteristic controlling cancer initiation and progression, and delineating TGF-<i>β</i> complexities according to these cancer traits, we identify the suppressive role of TGF-<i>β</i> in tumour initiation and early-stage progression and its promotive functionalities in cancer metastasis as well as other cancer hallmarks. We also propose the feasibility and possible scenarios of combining cold atmospheric plasma (CAP) with onco-therapeutics utilising TGF-<i>β</i> for cancer control given the intrinsic properties of CAP against cancer hallmarks.</p>","PeriodicalId":50462,"journal":{"name":"Expert Reviews in Molecular Medicine","volume":"24 ","pages":"e42"},"PeriodicalIF":4.5000,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Roles of TGF-<i>β</i> in cancer hallmarks and emerging onco-therapeutic design.\",\"authors\":\"Xiaofeng Dai,&nbsp;Dong Hua,&nbsp;Xiaoxia Lu\",\"doi\":\"10.1017/erm.2022.37\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Transforming growth factor-beta (TGF-<i>β</i>) is a double-edged sword in cancer treatment because of its pivotal yet complex and roles played during cancer initiation/development. Current anti-cancer strategies involving TGF-<i>β</i> largely view TGF-<i>β</i> as an onco-therapeutic target that not only substantially hinders its full utilisation for cancer control, but also considerably restricts innovations in this field. Thereby, how to take advantages of therapeutically favourable properties of TGF-<i>β</i> for cancer management represents an interesting and less investigated problem. Here, by categorising cancer hallmarks into four critical transition events and one enabling characteristic controlling cancer initiation and progression, and delineating TGF-<i>β</i> complexities according to these cancer traits, we identify the suppressive role of TGF-<i>β</i> in tumour initiation and early-stage progression and its promotive functionalities in cancer metastasis as well as other cancer hallmarks. We also propose the feasibility and possible scenarios of combining cold atmospheric plasma (CAP) with onco-therapeutics utilising TGF-<i>β</i> for cancer control given the intrinsic properties of CAP against cancer hallmarks.</p>\",\"PeriodicalId\":50462,\"journal\":{\"name\":\"Expert Reviews in Molecular Medicine\",\"volume\":\"24 \",\"pages\":\"e42\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2022-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Reviews in Molecular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/erm.2022.37\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Reviews in Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/erm.2022.37","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

转化生长因子-β (TGF-β)在癌症发生/发展过程中发挥着关键而复杂的作用,是癌症治疗中的一把双刃剑。目前涉及TGF-β的抗癌策略在很大程度上将TGF-β视为一种联合治疗的靶点,这不仅极大地阻碍了TGF-β在癌症控制中的充分利用,也极大地限制了该领域的创新。因此,如何利用TGF-β在治疗上的有利特性进行癌症治疗是一个有趣但研究较少的问题。本研究通过将癌症特征分类为控制癌症发生和进展的四个关键转变事件和一个使能特征,并根据这些癌症特征描述TGF-β的复杂性,我们确定了TGF-β在肿瘤发生和早期进展中的抑制作用,以及它在癌症转移和其他癌症特征中的促进作用。鉴于冷大气等离子体(CAP)对癌症特征的内在特性,我们还提出了将冷大气等离子体(CAP)与利用TGF-β的肿瘤治疗药物结合起来进行癌症控制的可行性和可能方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Roles of TGF-β in cancer hallmarks and emerging onco-therapeutic design.

Transforming growth factor-beta (TGF-β) is a double-edged sword in cancer treatment because of its pivotal yet complex and roles played during cancer initiation/development. Current anti-cancer strategies involving TGF-β largely view TGF-β as an onco-therapeutic target that not only substantially hinders its full utilisation for cancer control, but also considerably restricts innovations in this field. Thereby, how to take advantages of therapeutically favourable properties of TGF-β for cancer management represents an interesting and less investigated problem. Here, by categorising cancer hallmarks into four critical transition events and one enabling characteristic controlling cancer initiation and progression, and delineating TGF-β complexities according to these cancer traits, we identify the suppressive role of TGF-β in tumour initiation and early-stage progression and its promotive functionalities in cancer metastasis as well as other cancer hallmarks. We also propose the feasibility and possible scenarios of combining cold atmospheric plasma (CAP) with onco-therapeutics utilising TGF-β for cancer control given the intrinsic properties of CAP against cancer hallmarks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Expert Reviews in Molecular Medicine
Expert Reviews in Molecular Medicine BIOCHEMISTRY & MOLECULAR BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
7.40
自引率
1.60%
发文量
45
期刊介绍: Expert Reviews in Molecular Medicine is an innovative online journal featuring authoritative and timely Reviews covering gene therapy, immunotherapeutics, drug design, vaccines, genetic testing, pathogenesis, microbiology, genomics, molecular epidemiology and diagnostic techniques. We especially welcome reviews on translational aspects of molecular medicine, particularly those related to the application of new understanding of the molecular basis of disease to experimental medicine and clinical practice.
期刊最新文献
Cell therapy in Sjögren's syndrome: opportunities and challenges. Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity. Epigenetic changes in patients with post-acute COVID-19 symptoms (PACS) and long-COVID: A systematic review. Advances in multifunctional metal-organic framework (MOF)-based nanoplatforms for cancer starvation therapy. Thrombocytopenia in dengue infection: mechanisms and a potential application.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1